Akebia Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 167
- Market Cap
- $319.6M
- Website
- http://www.akebia.com
- Introduction
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- Drug: Erythropoiesis-Stimulating Agent (ESA)
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 500
- Registration Number
- NCT06901505
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT05082584
- Locations
- 🇺🇸
Research Site, Hackensack, New Jersey, United States
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT05082571
- Locations
- 🇺🇸
Research Site, Hackensack, New Jersey, United States
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
- Conditions
- Anemia Associated With Chronic Kidney Disease (CKD)
- Interventions
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 456
- Registration Number
- NCT04707768
- Locations
- 🇺🇸
Research Site, Woodbridge, Virginia, United States
🇺🇸Research Site#1, Coral Springs, Florida, United States
🇺🇸Research Site#2, Coral Springs, Florida, United States
Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT04707573
- Locations
- 🇺🇸
Research Site, Knoxville, Tennessee, United States
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 319
- Registration Number
- NCT04313153
- Locations
- 🇪🇸
Research Site, Valencia, Spain
🇪🇸Research Site #2, Barcelona, Spain
Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 54
- Registration Number
- NCT04299633
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
- Conditions
- Anemia Associated With Chronic Kidney Disease
- Interventions
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 46
- Registration Number
- NCT03992066
- Locations
- 🇺🇸
Research Site, Chattanooga, Tennessee, United States
Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin
- Conditions
- Drug Interaction Potentiation
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 134
- Registration Number
- NCT03801733
- Locations
- 🇨🇦
InVentiv Health Clinique Inc., Québec City, Quebec, Canada
Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin
- Conditions
- Drug Interaction Potentiation
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT03801746
- Locations
- 🇨🇦
inVentiv Health Clinique Inc., Québec City, Quebec, Canada